GlaxoSmithKline PLC — Director's Dealing 2016

Apr 1, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9552T

GlaxoSmithKline PLC

01 April 2016

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').

On 31 March 2016, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.05 per Ordinary Share, and notional ADSs at a price of $40.53 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2016:

Non Executive Director	Ordinary Shares	No. of ADSs
Sir Philip Hampton	3,113.879
Professor Sir Roy Anderson	511.566
Vindi Banga	1,512.456
Dr Stephanie Burns		678.178
Stacey Cartwright	378.114
Lynn  Elsenhans		1,389.096
Judy Lewent		526.173
Sir Deryck Maughan		1,356.357
Dr Daniel Podolsky		1,227.736
Urs Rohner	467.082
Hans Wijers	378.114

Jesse Goodman was appointed to the Board with effect from 1 January 2016.

In accordance with the share allocation arrangements for Non-Executive Directors, 25% of Jesse Goodman's fees will be retained and will be reinvested in the Company's ADSs at a future date, to be mutually agreed.

The Company and the Non-Executive Directors were advised of these allocations on 1 April 2016.

V A Whyte

Company Secretary

1 April 2016

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSZFLFBQZFXBBB